Humood Al Shmrany

Humood Al Shmrany

Auto-generated profile, based on publicly available information

Humood Al Shmrany

Department of Medical Laboratory, College of Applied Medical Science, Prince Sattam Bin Abdulaziz University, Alkharj 11942, Saudi Arabia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2025 in Salud, Ciencia y Tecnología
Verified
Journal Article
Open access
PDF file
HWHisham Ali Waggiallah
Hisham Ali Waggiallah
AAAbdulkareem Al-Garni
Abdulkareem Al-Garni
AGAisha Ali M Ghazwani
Aisha Ali M Ghazwani
ASAbdulkarim S. Bin Shaya
Abdulkarim S. Bin Shaya
HSHumood Al Shmrany
Humood Al Shmrany
YEYousif Elmosaad
Yousif Elmosaad
Artificial intelligence (AI) is rapidly altering the field of hematology, providing novel approaches to diagnosis, prognosis, and management of hematological illnesses. AI technologies, including machine learning (ML) and deep learning (DL), allow for the analysis of massive volumes of clinical, genetic, and imaging data, resulting in more accurate, rapid, and individualized care. In diagnostic hematology, AI is transforming blood smear analysis, bone marrow aspirations, and genomic profiling by automating cell classification, detecting anomalies, and discovering critical genetic changes associated with blood illnesses. AI-powered models are also improving prognostic skills by predicting disease progression, treatment response, and risk of relapse in illnesses such as leukemia, lymphoma, anemia, and myeloproliferative disorders. Furthermore, AI applications in precision medicine enable clinicians to adapt medicines based on individual genetic profiles, thereby increasing therapeutic success and reducing unwanted effects. The combination of AI and modern technology such as wearable health monitors and real-time diagnostic tools promises to improve patient management by providing proactive care via continuous monitoring and adaptive treatment options. As AI develops, it has enormous potential in hematology, enabling early identification, optimizing treatment regimens, and ultimately improving patient survival and quality of life. This study investigates the future implications of AI applications in hematology, emphasizing their revolutionary impact on diagnosis, prognosis, and individualized treatment techniques.

3 March 2025 in Salud, Ciencia y Tecnología
Verified
Journal Article
Open access
PDF file
MAMudathir Abdelshafea Abdelkareem Abakar
Mudathir Abdelshafea Abdelkareem Abakar
SKShamsoun Khamis Kafi
Shamsoun Khamis Kafi
RSRania Saad Suliman
Rania Saad Suliman
AGAisha Ali M Ghazwani
Aisha Ali M Ghazwani
HSHumood Al Shmrany
Humood Al Shmrany
HWHisham Ali Waggiallah
Hisham Ali Waggiallah
Introduction: Viral and tumor management are mediated by the production of CD137 as a co-receptor for T cells. Objective: The purpose of the research is to examine the link between soluble CD137 and the development of liver cirrhosis in HBV-infected people. Methods: Ninety individuals were recruited. A questionnaire was used to collect age and gender information. The serum quantities of soluble CD137, TNF-α, IFN-γ, IL-6, and IL-10 in the patients were measured using the ELISA technique. Real-Time-PCR was used to calculate the number of HBV DNA copies (viral load). HBV genotypes were determined using PCR, AST, and ALT levels were determined using a Mindary BS 120TM chemical auto-analyzer. Result: The study found significant positive associations between CD137 levels and TNF-γ (P=0.014/R=0.258) and IFN- (P=0.019/R=0.246), but not with IL-6 (P=0.579/R=0.059). There were no significant negative correlations between soluble CD137 levels and viral load (P=0.495/R=-0.073), IL-10 (P=0.474/R=-0.076), AST (P=0.140/R=-0.157), or ALT (P=0.140/R=-0.111). The highest mean of CD137 was detected in patients with pure genotype D, and the concentration of CD137 dropped as viral load increased. Conclusion: The considerable positive correlations of soluble CD137 with (TNFα- and IFN-γ) and the positive correlation with (IL-6) along with the negative correlations with viral load, AST, ALT, and IL-10 may indicate that CD137 has a beneficial effect on the prognosis of HBV infection. There was significant influence of a specific HBV genotype on CD137 expression.